All Categories
Can academia save the pharmaceutical industry? The pharmaceutical industry is at a crossroads. The urgent needfor novel therapies cannot stem the skyrocketing costs andplummeting productivity plaguing R&D, and many key products arefacing patent expiration. Dr. Rathnam Chaguturu presents a case forcollaboration between the pharmaceutical industry and academia thatcould reverse the industry's decline. CollaborativeInnovation in Drug Discovery: Strategies for Public and PrivatePartnerships provides insight into the potential synergyof basing R&D in academia while leaving drug companies to turnhits into marketable products. As Founder and CEO ofiDDPartners, focused on pharmaceutical innovation, Foundingpresident of the International Chemical Biology Society, and SeniorDirector-Discovery Sciences, SRI International, Dr. Chaguturu hasassembled a panel of experts from around the world to weigh in onissues that affect the two driving forces in medicaladvancement.Gain global perspectives on the benefits and potential issuessurrounding collaborative innovationDiscover how industries can come together to prevent another"Pharma Cliff"Learn how nonprofits are becoming the driving force behindinnovationRead case studies of specific academia-pharma partnerships forreal-life examples of successful collaborationExplore government initiatives that help foster cooperationbetween industry and academiaDr. Chaguturu’s thirty-five years of experience inacademia and industry, managing new lead discovery projects andforging collaborative partnerships with academia, diseasefoundations, nonprofits, and government agencies lend him aninformative perspective into the issues facing pharmaceuticalprogress. In Collaborative Innovation in Drug Discovery:Strategies for Public and Private Partnerships, he and hisexpert team provide insight into the various nuances of thedebate.